SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/20.06.25

SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/20.06.25 Share Price

DE000SY08XT2

Market Closed - Boerse Frankfurt Warrants 20:40:21 05/07/2024 BST
3.38 ^EUR	-1.46%

Current month

-6.16%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/20.06.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
05/07/24	3.35	-2.33%
04/07/24	3.43	-0.29%
03/07/24	3.44	+1.18%
02/07/24	3.4	-2.02%
01/07/24	3.47	-2.80%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 08:40 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SY08XT
ISIN	DE000SY08XT2
Date issued	04/06/2024
Strike	450 $
Maturity	20/06/2025 (350 Days)
Parity	10 : 1
Emission price	4.22 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.82 €
Lowest since issue	3.16 €
Delta	-0.31x
Omega	4.036
Premium	12.89x
Gearing	12.93x
Moneyness	0.9484
Difference Strike	-24.48 $
Difference Strike %	-5.44%
Spread	0.05 €
Spread %	1.47%
Theoretical value	3.385
Implied Volatility	32.76 %
Total Loss Probability	56.71 %
Intrinsic value	0.000000
Present value	3.385
Break even	413.30 €
Theta	-0.03x
Vega	0.15x
Rho	-0.16x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company